Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.

P Hildebrand; C Beglinger; K Gyr; J B Jansen; L C Rovati; M Zuercher; C B Lamers; I Setnikar; G A Stalder

doi:10.1172/JCI114486

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Hildebrand, P. in: JCI | PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Beglinger, C. in: JCI | PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Gyr, K. in: JCI | PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Jansen, J. in: JCI | PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Rovati, L. in: JCI | PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Zuercher, M. in: JCI | PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Lamers, C. in: JCI | PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Setnikar, I. in: JCI | PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Stalder, G. in: JCI | PubMed | Google Scholar

Published in Volume 85, Issue 3 on March 1, 1990
J Clin Invest. 1990;85(3):640–646. https://doi.org/10.1172/JCI114486.
© 1990 The American Society for Clinical Investigation

Published March 1, 1990 - Version history

The present study was designed (a) to characterize the activity of loxiglumide as a peripheral cholecystokinin (CCK) antagonist in healthy human subjects, and (b) to determine whether CCK is a physiologic regulator of the intestinal phase of meal-stimulated exocrine pancreatic and biliary secretions in man. Intravenous loxiglumide (22 mumol/kg per h) was highly potent in antagonizing CCK8-induced pancreatic enzyme and bile acid secretion as well as pancreatic polypeptide release. The potency and selectivity of loxiglumide as an antagonist of CCK provides the tool for evaluating the role of CCK as a physiological mediator of meal-induced pancreatic and biliary responses in humans. Infusion of a liquid test meal into the duodenum evoked an immediate response of pancreatic enzyme and bilirubin outputs, respectively. Intravenous loxiglumide significantly inhibited the meal-induced pancreatic amylase output by 63% (P less than 0.05), lipase output by 43% (P less than 0.05), and bilirubin output by 59% (P less than 0.05). These data suggest that CCK is a physiological mediator of the intestinal phase of meal-stimulated pancreatic and biliary responses.

Version 1 (March 1, 1990): No description

Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.

P Hildebrand, C Beglinger, K Gyr, J B Jansen, L C Rovati, M Zuercher, C B Lamers, I Setnikar, and G A Stalder

Article tools

Metrics

Go to

Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.

P Hildebrand, C Beglinger, K Gyr, J B Jansen, L C Rovati, M Zuercher, C B Lamers, I Setnikar, and G A Stalder

Article tools

Metrics

Go to

Sign up for email alerts